Drug intelligence / Profile preview

colistin + tobramycin + nystatin

Development stage
Preclinical
Lead developer
PureIMS
Modality
Peptides, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
Administration
Intravenous, Inhalation, Oral, Topical, Ophthalmic, Intramuscular
01

Overview

This is a combination of three antimicrobial agents—colistin, tobramycin, and nystatin. Colistin (also known as polymyxin E) is a polymyxin antibiotic that disrupts the bacterial cell membrane of Gram-negative bacteria, leading to cell death. Tobramycin is an aminoglycoside antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit in susceptible bacteria, particularly effective against Pseudomonas aeruginosa and other Gram-negative organisms. Nystatin is a polyene antifungal agent that binds to ergosterol in fungal cell membranes, increasing permeability and causing leakage of cellular contents; it is primarily active against Candida species. This combination may be used for topical or inhalational therapy in settings where mixed infections with resistant Gram-negative bacteria (such as Pseudomonas aeruginosa) and fungi are suspected or confirmed—for example, in cystic fibrosis patients with chronic airway colonization/infection[1][3][4]. The use of colistin-tobramycin combinations has been shown to be more effective than monotherapy for eradicating biofilms formed by Pseudomonas aeruginosa[1][2]. Nystatin adds antifungal coverage.

Other names
Selective Decontamination of the Digestive TractSDD regimenSDD Oral PasteSDD Gastric Suspension
02

Targets

Ergosterol30S A-site (Bacterial ribosomal 30S A-site)Lipid A

Beyond the preview

Go deeper on colistin + tobramycin + nystatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on colistin + tobramycin + nystatin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call